Abstract:Abstract Background Chronic lesions of small blood vessels and capillaries may play a role in the pathogenesis of depression. As the genes associated with these vascular risk factors may be involved in depression, these genetic polymorphisms may affect the efficacy of antidepressants. This study was performed to investigate the roles of methylenetetrahydrofolate reductase (MTHFR), apolipoprotein E (ApoE), and apolipoprotein A4 (ApoA4) genetic polymorphisms in antidepressant response in depressive patients.Methods A total of 281 Han Chinese patients received a single antidepressant drug for at least 6 weeks. The Hamilton Depression Rating Scale (HAMD-17) was used to evaluate the severity of depressive symptoms and the therapeutic effects of the drug administered. Eight single nucleotide polymorphisms (SNPs) of MTHFR, ApoE, and ApoA4 genes were detected using gene chips. Differences in clinical variables between the responders and non-responders, as well as between remission and non-remission groups, were examined using the independent samples t test and Pearson’s χ 2 test. In addition, the associations of single loci and haplotypes with treatment response were analyzed.Results Among the eight SNPs in four genes, two SNPs (ApoA4 rs5101 and rs675) were eliminated as they had a MAF < 5%.Haplotype(C-A) in MTHFR (rsl801133 and rs1801131) was significantly associated with better antidepressant response in the 8-week antidepressant group overall ( P = 0.0007), and in the male subgroup ( P = 0.003), and serotonin norepinephrine reuptake inhibitor (SNRI) subgroup ( P = 0.001). The ApoE rs405509 C allele was significantly associated with poorer antidepressant response in the 6-week male subgroup ( P = 0.004), while the 405509 AA genotype was associated with better antidepressant efficacy in the 6-week antidepressant group overall ( P = 0.006) and male subgroup ( P = 0.002).Conclusions Genetic polymorphisms of MTHFR, ApoE, and ApoA4 may be associated with the efficacy of antidepressants, in which the haplotype (rs1801131-rs1801133) A–C type was associated with better antidepressant efficacy, especially in males and in patients using SNRIs. The efficacy of antidepressants may be better in ApoE rs405509 A allele and AA genotype carriers, but worse in ApoA4 rs5092 G allele and GG genotype carriers.

CYP1A2 Genetic Polymorphism is Associated with Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population

Association Of Brain-Derived Neurotrophic Factor Genetic Val66met Polymorphism With Severity Of Depression, Efficacy Of Fluoxetine And Its Side Effects In Chinese Major Depressive Patients

No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.

No Association Between <i>SLC6A4</i> Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients

No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients

Association between SLC17A7 gene polymorphisms and venlafaxine for major depressive disorder in a Chinese Han population: a prospective pharmacogenetic case-control study

GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.

A Novel NR3C2 Polymorphism and the Increased Thyroid-Stimulating Hormone Concentration Are Associated with Venlafaxine Treatment Outcome in Chinese Han MDD Patients

GSK-3 Beta and BDNF Genes May Not Be Associated with Venlafaxine Treatment Response in Chinese of Han Ethnicity

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.

Htr1a And Htr2a Variants May Not Predict Venlafaxine Treatment Response In China Han Population With Major Depressive Disorder

Association of APC and REEP5 Gene Polymorphisms with Major Depression Disorder and Treatment Response to Antidepressants in a Han Chinese Population

Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.

Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response

Epistatic Interaction Between 5-HT1A and Vascular Endothelial Growth Factor Gene Polymorphisms in the Northern Chinese Han Population with Major Depressive Disorder

Association Study of GABRB2 gene and antidepressant response to SNRI in patients with major depression.

The Relationship Between Single Nucleotide Polymorphisms in 5-HT2A Signal Transduction-Related Genes and the Response Efficacy to Selective Serotonin Reuptake Inhibitor Treatments in Chinese Patients with Major Depressive Disorder

5-Htr1a And 5-Htr2a Genetic Polymorphisms And Ssri Antidepressant Response In Depressive Chinese Patients

Association Study of Multidrug Resistance 1 Gene Polymorphisms with Efficacy and Adverse Drug Reaction of Paroxetine in Major Depressive Patients

Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated with Antidepressant Efficacy in Major Depressive Disorder